New Management in Pharma: Insiderism
Executive Summary
Big Pharma is under the gun, with plenty of top management changes. By early next year, the industry will have seen five new CEOs; five new CFOs; a handful of changes in the top R&D spots, and a couple of new commercial bosses, all announced since the beginning of 2007 (an exhibit charts the changes). Of the sixteen job changes, six came about because the predecessor in the job was, if not outright fired, at least pressured to leave. But how much change are we really going to see?
You may also be interested in...
The Device Industry's Training Ground
Are successful medical device start-ups born or made? It's not clear, but Stanford University's Emerging Entrepreneur program is attempting to incorporate the experience of successful start-ups in a hnew learning program.
A Look Back at 2006: The Pipeline Challenge
Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.
Pfizer's Change Management: Unfamiliar Faces
The dust at Pfizer still hasn't settled as new CEO Jeff Kindler shakes up the senior office suite at the world's largest pharmaceutical company. But the dust hasn't obscured the basic message: Pfizer's strategic and managerial model hasn't worked. What's more, the Big Pharma's board is one of a handful in the industry coming to similar conclusions.